News

Jens K. Munk joined the ilochip team on January 5th, 2009, as a Research Scientist. His main responsibilities are development of reagent stability on the ilochip platform and other things relating to the development of a stand-alone Diagnostic system.

Jens has a background as a biochemist from the University of Southern Denmark, where he received his M. Sc. In December 2002. Since then he has worked on developing dietetic animal feeds with Biofiber-Damino; most recently he was employed at Chempaq, where he was responsible for embedding new analyses into that company’s blood analysis platform.

Katja N. Olsen joined the ilochip team on 1st December 2008 as a Senior Research Scientist.

Katja has a background as chemical engineer from DTU (2000) and a Ph.D.-degree from The Royal Veterinary and Agricultural University (RVAU) (2004). She is specialized in the area of microbiology and chemical engineering. 
From April 2007 Katja worked as a research scientist in a collaboration between ilochip A/S and DTU. Her main responsibilities were the development of an assay for detection of Campylobacter in chicken houses and implementation of this on ilochip’s technology platform.

November 15th ilochip moved the R & D facilities to Copenhagen. Ilochip entered into a rent and service agreement with DTU Chemical Institute.
The R & D facility address is: ilochip A/S, DTU Kemitorvet Building 206, 2800 Kgs. Lyngby.

1st November 2008 ilochip has been granted Dkr. 5,0 mill in a combined EU and Danish Agency for Science, Technology and Innovation funding under the new established Eurostars - Eureka regime. Ilochip forms a project consortium with Rijksinstitut voor Volksgezondhit en Mileu in Holland and thinXXS in Germany within the Eurostars project PathoDetect.
Together the consortium will over a 3 years period develop the First Fully Integrated On-site Airborne Pathogen Detector.

In a recent office action from the European Patent Organisation (EPO), the examination process has concluded that with minor changes to the description section, the patent application EP1730276 entitled METHOD, CHIP, DEVICE AND SYSTEM FOR EXTRACTION OF BIOLOGICAL MATERIALS and covering ilochip's electrolysis technology for the extraction of nucleic acids can be granted with all of the original 19 claims intact.  This is a milestone in the company's history and lays the foundation for commercial exploitation of the electrolysis technology and it's inclusion in the company's integrated platform for the detection of airborne pathogens.  The patent is expected to be issued in the 3rd quarter of 2008.

This is the first of three european patent applications within the three patent families protecting ilochip's core technology to be granted.  Decisions on the other two European applications are pending.  The patent families are also being prosecuted in other countries relevant for the commercial markets ilochip expect's to operate within.

Further information can be obtained from CSO, Kenneth W. Harlow.

ilochip A/S announced today, that effective February 1^st 2008, Casper Breum has been appointed to the position of Chief Executive Officer for the company. He succeeds Jes Østergaard who for the past two years has served as ilochip's CEO. Østergaard remains a member of the ilochip Board of Directors, and will continue to be actively involved in the company's continuing development by providing continuity during the CEO transition and by maintaining an active working relationship to the company's activities through his Board of Directors responsibilities.

"The appointment of Casper Breum as new ilochip CEO is a very positive step for the company", Erling Andersen, Chairman of the Board of Directors remarks and continues: "The company is now ready to take the final steps towards product commercialization, and I am convinced that Casper Breum's qualifications and background within specific high prioritized fields are exactly what ilochip needs at this point".

"At the same time, I would like to thank Jes Østergaard for all of the good results that have been achived throughout the past two years" Erling Andersen adds.

Prior to being named ilochip CEO, Casper Breum has served as Business Development Manager at the pharmaceutical company H. Lundbeck A/S. Before that, he also served in a number of different roles at Lundbeck, Niels Clauson-Kaas and Novo Nordisk.

Casper Breum holds a M.Sc. in Chemical Engineering as well as an MBA in Technology Management from the Technical University of Denmark. He is married and has two children.

For more details, please contact:

Casper Breum
CEO, ilochip A/S
Phone: +45 4045 5969

Mogens Kaiser
CFO, ilochip A/S
Phone: +45 4056 1418

At an extraordinary shareholder meeting January 2^nd 2008 ilochip investors decided to convert loans to equity capital and to inject new capital as cash.

Dkr. 16.4 mill was converted and Dkr. 3.75 mill will be paid in cash.

All transactions were made by present investors.